- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: 52.72%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 (10) | -0.64 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2022 (9) | -0.14 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2021 (8) | 0.33 | -2.94 | 0.14 | -44.0 | 0.00 | 0 | 42.42 | -42.3 | 0.00 | 0 | 42.42 | -42.3 |
2020 (7) | 0.34 | -33.33 | 0.25 | -16.67 | 0.00 | 0 | 73.53 | 25.0 | 0.00 | 0 | 73.53 | 25.0 |
2019 (6) | 0.51 | 0 | 0.30 | 0 | 0.00 | 0 | 58.82 | 0 | 0.00 | 0 | 58.82 | 0 |
2018 (5) | -1.24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2017 (4) | 0.36 | 63.64 | 0.13 | 0 | 0.00 | 0 | 36.11 | 0 | 0.00 | 0 | 36.11 | 0 |
2016 (3) | 0.22 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
---|---|---|---|---|---|---|---|---|---|
24Q3 (20) | 0.05 | -68.75 | 150.0 | 0.06 | -33.33 | 140.0 | 0.24 | 26.32 | 163.16 |
24Q2 (19) | 0.16 | 433.33 | 0 | 0.09 | 228.57 | 200.0 | 0.19 | 533.33 | 167.86 |
24Q1 (18) | 0.03 | 111.54 | 110.34 | -0.07 | 75.0 | 73.08 | 0.03 | 104.69 | 110.34 |
23Q4 (17) | -0.26 | -160.0 | -85.71 | -0.28 | -86.67 | -154.55 | -0.64 | -68.42 | -357.14 |
23Q3 (16) | -0.10 | 0 | 0 | -0.15 | -66.67 | -66.67 | -0.38 | -35.71 | 0 |
23Q2 (15) | 0.00 | 100.0 | -100.0 | -0.09 | 65.38 | -550.0 | -0.28 | 3.45 | -2900.0 |
23Q1 (14) | -0.29 | -107.14 | -222.22 | -0.26 | -136.36 | -188.89 | -0.29 | -107.14 | -222.22 |
22Q4 (13) | -0.14 | 0 | -133.33 | -0.11 | -22.22 | 15.38 | -0.14 | 0 | -142.42 |
22Q3 (12) | 0.00 | -100.0 | 0 | -0.09 | -550.0 | -325.0 | 0.00 | -100.0 | -100.0 |
22Q2 (11) | 0.10 | 211.11 | -56.52 | 0.02 | 122.22 | -93.94 | 0.01 | 111.11 | -97.37 |
22Q1 (10) | -0.09 | -50.0 | -156.25 | -0.09 | 30.77 | -181.82 | -0.09 | -127.27 | -156.25 |
21Q4 (9) | -0.06 | 0 | -126.09 | -0.13 | -425.0 | -218.18 | 0.33 | -15.38 | -2.94 |
21Q3 (8) | 0.00 | -100.0 | 100.0 | 0.04 | -87.88 | 0.0 | 0.39 | 2.63 | 254.55 |
21Q2 (7) | 0.23 | 43.75 | 360.0 | 0.33 | 200.0 | 1750.0 | 0.38 | 137.5 | 216.67 |
21Q1 (6) | 0.16 | -30.43 | 128.57 | 0.11 | 0.0 | 83.33 | 0.16 | -52.94 | 128.57 |
20Q4 (5) | 0.23 | 2400.0 | -48.89 | 0.11 | 175.0 | -35.29 | 0.34 | 209.09 | -33.33 |
20Q3 (4) | -0.01 | -120.0 | 0.0 | 0.04 | 300.0 | 0.0 | 0.11 | -8.33 | 0.0 |
20Q2 (3) | 0.05 | -28.57 | 0.0 | -0.02 | -133.33 | 0.0 | 0.12 | 71.43 | 0.0 |
20Q1 (2) | 0.07 | -84.44 | 0.0 | 0.06 | -64.71 | 0.0 | 0.07 | -86.27 | 0.0 |
19Q4 (1) | 0.45 | 0.0 | 0.0 | 0.17 | 0.0 | 0.0 | 0.51 | 0.0 | 0.0 |
年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
---|---|---|---|---|---|---|---|---|---|---|
2024/10 | 0.26 | 28.08 | 87.17 | 1.98 | 16.11 | 0.71 | N/A | 本月營收較去年同期增加87.18%,主要係新增子公司業務所致。 | ||
2024/9 | 0.2 | -20.97 | 54.76 | 1.72 | 9.87 | 0.68 | 0.72 | 本月營收較去年同期增加54.76%,主要係新增子公司業務所致。 | ||
2024/8 | 0.26 | 12.8 | 52.79 | 1.52 | 5.81 | 0.7 | 0.7 | 本月營收較去年同期增加52.79%,主要係新增子公司業務所致。 | ||
2024/7 | 0.23 | 2.62 | 11.63 | 1.27 | -0.35 | 0.7 | 0.7 | - | ||
2024/6 | 0.22 | -13.73 | 62.09 | 1.04 | -2.62 | 0.65 | 0.77 | 本月營收較去年同期增加62.10%,主要係新增子公司業務所致。 | ||
2024/5 | 0.26 | 43.73 | 16.7 | 0.82 | -12.03 | 0.64 | 0.78 | - | ||
2024/4 | 0.18 | -14.91 | -15.6 | 0.57 | -20.83 | 0.44 | 1.14 | - | ||
2024/3 | 0.21 | 310.35 | -4.73 | 0.39 | -23.01 | 0.39 | 1.42 | - | ||
2024/2 | 0.05 | -60.46 | -62.83 | 0.18 | -37.05 | 0.28 | 1.96 | 本月營收較去年同期減少 62.84%,主要係消化器類癌症用藥結束代理減少營收所致。 | ||
2024/1 | 0.13 | 26.97 | -13.27 | 0.13 | -13.27 | 0.35 | 1.57 | - | ||
2023/12 | 0.1 | -15.38 | -54.45 | 1.93 | -25.39 | 0.36 | 1.53 | 本月營收較去年同期減少54.46%,主要係健檢事業營收減少所致。 | ||
2023/11 | 0.12 | -13.13 | -57.15 | 1.83 | -22.65 | 0.39 | 1.42 | 本月營收較去年同期減少57.16%,主要係健檢事業營收減少所致。 | ||
2023/10 | 0.14 | 5.9 | -46.32 | 1.71 | -18.02 | 0.44 | 1.26 | - | ||
2023/9 | 0.13 | -21.98 | -41.97 | 1.57 | -14.03 | 0.5 | 1.22 | - | ||
2023/8 | 0.17 | -17.57 | -30.53 | 1.44 | -10.12 | 0.51 | 1.21 | - | ||
2023/7 | 0.2 | 49.01 | 50.81 | 1.27 | -6.51 | 0.56 | 1.09 | 本月營收較去年同期增加50.82%,主要係健檢事業營收增加所致。 | ||
2023/6 | 0.14 | -37.89 | -21.35 | 1.07 | -12.79 | 0.57 | 1.22 | - | ||
2023/5 | 0.22 | 3.94 | -6.26 | 0.93 | -11.38 | 0.65 | 1.06 | - | ||
2023/4 | 0.21 | -3.96 | -15.2 | 0.72 | -12.84 | 0.57 | 1.22 | - | ||
2023/3 | 0.22 | 60.09 | 12.21 | 0.5 | -11.82 | 0.5 | 1.61 | - | ||
2023/2 | 0.14 | -7.73 | 10.09 | 0.29 | -24.28 | 0.51 | 1.59 | - | ||
2023/1 | 0.15 | -33.31 | -41.22 | 0.15 | -41.22 | 0.65 | 1.24 | - | ||
2022/12 | 0.22 | -20.4 | 9.64 | 2.59 | -26.45 | 0.76 | 1.45 | - | ||
2022/11 | 0.28 | 8.82 | 29.34 | 2.36 | -28.66 | 0.76 | 1.45 | - | ||
2022/10 | 0.26 | 14.48 | 11.52 | 2.08 | -32.72 | 0.72 | 1.52 | - | ||
2022/9 | 0.22 | -6.59 | 11.75 | 1.83 | -36.27 | 0.6 | 2.1 | - | ||
2022/8 | 0.24 | 78.93 | -10.01 | 1.6 | -39.89 | 0.55 | 2.3 | - | ||
2022/7 | 0.13 | -22.29 | -33.17 | 1.36 | -43.22 | 0.54 | 2.33 | - | ||
2022/6 | 0.17 | -25.97 | -72.71 | 1.23 | -44.14 | 0.65 | 2.11 | 本月營收較去年同期減少 72.72%,主要係熟齡女性保健食品結束代理減少營收所致。 | ||
2022/5 | 0.23 | -5.96 | -29.62 | 1.05 | -32.56 | 0.68 | 2.04 | - | ||
2022/4 | 0.25 | 27.08 | -25.46 | 0.82 | -33.36 | 0.57 | 2.43 | - | ||
2022/3 | 0.2 | 57.07 | -35.12 | 0.57 | -36.28 | 0.57 | 1.8 | - | ||
2022/2 | 0.12 | -50.74 | -50.06 | 0.38 | -36.87 | 0.58 | 1.78 | 本月較去年同期減少50.07%,主係受新冠肺炎疫情亦趨嚴峻而影響營收所致。 | ||
2022/1 | 0.25 | 24.39 | -27.43 | 0.25 | -27.43 | 0.67 | 1.53 | - | ||
2021/12 | 0.2 | -6.1 | -20.15 | 3.52 | -2.55 | 0.65 | 1.69 | - | ||
2021/11 | 0.22 | -6.17 | -46.29 | 3.31 | -1.21 | 0.65 | 1.7 | - | ||
2021/10 | 0.23 | 14.72 | -32.9 | 3.1 | 4.93 | 0.7 | 1.57 | - | ||
2021/9 | 0.2 | -24.78 | -38.49 | 2.87 | 9.91 | 0.67 | 1.82 | - | ||
2021/8 | 0.27 | 32.87 | -5.88 | 2.66 | 16.84 | 1.1 | 1.11 | - | ||
2021/7 | 0.2 | -68.27 | -26.11 | 2.4 | 20.08 | 1.17 | 1.05 | - | ||
2021/6 | 0.63 | 90.95 | 121.48 | 2.2 | 27.36 | 1.3 | 1.06 | 本月營收較去年同期增加 121.49%,主要係熟齡女性保健食品銷售增加所致。 | ||
2021/5 | 0.33 | -0.4 | 26.47 | 1.56 | 8.65 | 0.97 | 1.42 | - | ||
2021/4 | 0.33 | 10.6 | 12.72 | 1.23 | 4.68 | 0.88 | 1.55 | - | ||
2021/3 | 0.3 | 20.9 | -8.06 | 0.9 | 1.98 | 0.9 | 2.04 | - | ||
2021/2 | 0.25 | -28.42 | -9.86 | 0.6 | 7.92 | 0.85 | 2.15 | - | ||
2021/1 | 0.35 | 36.88 | 25.69 | 0.35 | 25.69 | 1.0 | 1.82 | - | ||
2020/12 | 0.25 | -36.84 | -47.26 | 3.61 | -16.67 | 1.0 | 1.55 | - | ||
2020/11 | 0.4 | 17.22 | 39.62 | 3.35 | -12.84 | 1.07 | 1.44 | - | ||
2020/10 | 0.34 | 5.15 | -5.28 | 2.95 | -17.09 | 0.95 | 1.62 | - | ||
2020/9 | 0.33 | 15.09 | 23.5 | 2.61 | -18.43 | 0.88 | 1.63 | - | ||
2020/8 | 0.28 | 4.31 | -30.16 | 2.28 | -22.21 | 0.84 | 1.71 | - | ||
2020/7 | 0.27 | -4.89 | -20.46 | 2.0 | -20.93 | 0.82 | 1.76 | - | ||
2020/6 | 0.29 | 9.03 | -24.49 | 1.72 | -21.0 | 0.84 | 1.8 | - | ||
2020/5 | 0.26 | -11.23 | -28.88 | 1.44 | -20.27 | 0.89 | 1.72 | - | ||
2020/4 | 0.3 | -9.79 | -23.86 | 1.18 | -18.06 | 0.9 | 1.69 | - | ||
2020/3 | 0.33 | 18.52 | 7.02 | 0.88 | -15.91 | 0.88 | 1.61 | - | ||
2020/2 | 0.28 | -0.18 | 27.8 | 0.55 | -25.38 | 1.04 | 1.37 | - | ||
2020/1 | 0.28 | -42.57 | -47.28 | 0.28 | -47.28 | 1.05 | 1.36 | - | ||
2019/12 | 0.48 | 67.21 | 0.53 | 4.33 | -18.8 | 0.0 | N/A | - | ||
2019/11 | 0.29 | -20.47 | -21.14 | 3.85 | -20.71 | 0.0 | N/A | - |